Home    中文  
 
  • Search
  • lucene Search
  • Citation
  • Fig/Tab
  • Adv Search
Just Accepted  |  Current Issue  |  Archive  |  Featured Articles  |  Most Read  |  Most Download  |  Most Cited

Chinese Journal of Clinicians(Electronic Edition) ›› 2025, Vol. 19 ›› Issue (03): 229-233. doi: 10.3877/cma.j.issn.1674-0785.2025.03.010

• Review • Previous Articles    

Progress in research of S100B protein in cardiovascular diseases

Meiqin Wang1, Haitao Pan1, Xiangfei Chen1, Wan Wu1, Yuhe Zhou1,(), Yanqing Wang1   

  1. 1. Department of General Practice,General Hospital of the Eastern Theater Command of the People's Liberation Army of China,Nanjing 210000,China
  • Received:2025-02-26 Online:2025-03-15 Published:2025-06-20
  • Contact: Yuhe Zhou

Abstract:

S100B is a calcium binding protein,mainly secreted by astrocytes,Schwann cells,and oligodendrocytes in the nervous system.It is commonly used clinically to evaluate brain injury and its severity.As a damage-associated molecular pattern protein,S100B can also be secreted in cardiomyocytes,causing damage to the endothelium of cardiac blood vessels,inducing apoptosis of cardiomyocytes,disrupting calcium ion homeostasis in cardiomyocytes,inhibiting the intrinsic nervous system of the heart,leading to myocardial injury and ventricular remodeling,and inducing cardiovascular events.This article reviews the progress in the research of S100B protein in cardiovascular diseases,opening up the perspective that S100B protein may be considered as a diagnostic and therapeutic target for cardiovascular diseases.

Key words: Biomarker, Inflammation, Apoptosis, S100B, Cardiovascular disease

京ICP 备07035254号-20
Copyright © Chinese Journal of Clinicians(Electronic Edition), All Rights Reserved.
Tel: 010-57830845 E-mail: zhlcyszz@cma.org.cn
Powered by Beijing Magtech Co. Ltd